A combination of ipilimumab and nivolumab has a significant impact on the five year median overall survival and progression free survival of patients with advanced melanoma compared to either drug alone, the latest analysis from CheckMate 067 shows. The Phase III study randomised 945 patients with previously untreated stage III or IV melanoma in a 1:1:1 ...
Combination immunotherapy boosts survival in advanced melanoma
By Nicola Garrett
2 Oct 2019